Gedea Biotech granted European Patent for its treatment pHyph for women with vaginal fungal infections
Patent now valid in two of the world’s largest markets, Europe and USA until 2037
Lund, Sweden, October 25, 2021. Swedish women’s health company Gedea Biotech today announced that the company has been granted a patent from the European Patent Office, covering the treatment of fungal infections with compound glucono-δ-lactone (GDL). The patent numbered EP 3 439 633 is valid in 36 European countries and can be kept in force until the 6th of April 2037. This follows previously announced patent rights valid in United States. Gedea Biotech has previously announced that the corresponding patent is approved in the USA. Both patents comprise the use of the ingredient GDL in pHyph. GDL is a well-documented substance with a low risk of developing resistance.
The huge problem of antimicrobial resistance (AMR) in vaginal fungal infections is frequently addressed by gynecologists and public health experts. Candida albicans, which is the most common cause of vaginal fungal infection, is also a common cause of oral infections in patients with weakened immune systems and in the intestinal system of premature babies. According to the World Health Organization, WHO, antimicrobial resistance is one of the greatest threats to global public health today. (https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance).
Annette Säfholm, Gedea Biotech’s CEO comments: "The currently approved European patent is part of our IP strategy. Hence, we have established exclusivity for our products in all important markets. In previous studies, Gedea has documented clinically relevant results with pHyph for the treatment of bacterial vaginosis and a follow-up, placebo-controlled study with the aim to confirm these results are currently being conducted at several European clinics. A study on vaginal fungal infection has been carried out with promising results and will be followed up with a larger study starting in Q1, 2022."
Gedea Biotech has previously been granted patents in the United States, Eurasia (including Russia) and Israel for the treatment of vaginal fungal infections with GDL (pHyph). The corresponding patent is also expected to be granted in Japan shortly.
For further information, please contact:
Annette Säfholm, CEO Gedea Biotech
Telephone: +46 708 - 91 86 81
Email: annette.safholm@gedeabiotech.com
About Gedea Biotech
Gedea Biotech is a Swedish, innovative women’s health company developing pHyph, an antibiotic-free and effective treatment for bacterial vaginosis. The company has generated promising results for the treatment of vaginal fungal infection and further studies are planned. Vaginal infections affect at least 400 million women every year worldwide and the market is worth over $ 1.5 billion. Gedea Biotech was founded in 2015 in Lund, Sweden. https://gedeabiotech.com/.
Tags:
